Overall market sentiment for one. Appetite for risk among HNIs has gone up with the Nifty now within sight of a record. The matter of expensive valuation remains though
A new report from Motilal Oswal notes that increasingly Indian pharma companies are finding it hard to meet the compliance criteria set by USFDA, leading to regulatory hurdles for the US generics market.